1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Sanofi India Limited

Sanofi India Limited

SANOFI.BO
Sanofi India LimitedIN flagBombay Stock Exchange
3,400.00
INR
+20.75
- -
78.36BMarket Cap
Sanofi India Limited
SANOFI.BO
(Bombay Stock Exchange)

Recent

price

3,400.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
471.09
559.85
679.01
780.34
851.23
943.14
1,037.23
1,070.88
1,189.59
1,307.09
1,245.3
1,269.31
1,184.16
860.42
863.63
791.73
860.21
Revenue per Share
67.31
83.01
76.71
115.14
114.46
139.6
132.09
141.55
165.26
179.85
207.38
410.06
269.47
261.78
179.54
141.85
157.4
Basic EPS, GAAP
42.24
60.49
125.82
118.34
115.04
92.57
139.86
164.17
136.64
146.11
247.37
232.65
163.48
85.15
184.67
179.15
- -
Free Cash Flow per Basic Share
23.9
63.92
38.35
45.4
52.65
63.65
65
68.04
71.04
66
349.01
364.99
683
377.02
167
192.01
- -
Dividend per Share
339.32
375.88
406.57
457.33
506.64
607.41
658.73
717.91
798.11
891.25
745.79
789.43
376.11
271.2
203.56
154.14
9.99
Book Value per Share
436.81
236.5
289.58
367.42
443.85
622.91
702.37
780.61
881.26
995.02
871.8
964.11
551.74
437.55
373.11
325
339.2
Tangible Book Value per Share
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
23
Basic Weighted Avg Shares
10,850
12,894
15,638
17,972
19,604
21,721
23,888
24,663
27,397
30,103
28,680
29,233
27,272
19,816
19,890
18,234
19,811
Sales/Revenue/Turnover
21.76
16.82
14.2
17.37
12.62
16.01
17.43
17.69
19.08
18.85
22.1
23.8
24.41
22.88
22.81
24.9
23.6
Operating Margin (%)
197
312
899
923
966
1,130
1,188
1,022
1,027
999
822
667
419
396
382
373
373
Depreciation Expense
1,550
1,912
1,767
2,652
2,636
3,215
3,042
3,260
3,806
4,142
4,776
9,444
6,206
6,029
4,135
3,267
3,625
Net Income, GAAP
31.74
32.68
32.5
33.95
35.62
40.14
36.68
36.65
37.59
30.96
29.47
24.9
28.2
31.01
27.28
26.53
26.65
Effective Tax Rate (%)
14.29
14.83
11.3
14.76
13.45
14.8
12.73
13.22
13.89
13.76
16.65
32.31
22.76
30.42
20.79
17.92
18.3
Profit Margin (%)
8,196
3,098
4,420
4,782
6,070
7,560
10,732
8,421
9,687
14,259
11,465
13,883
8,697
5,967
3,903
3,092
3,583
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
179
176
149
139
140
137
168
LT Debt
10,142
11,166
12,041
13,467
14,858
17,585
18,830
20,264
22,192
24,423
21,190
22,256
12,758
10,152
8,606
7,492
7,821
Total Equity
16.56
13.72
12.94
16.19
11.26
12.65
14.17
13.89
15.1
16.48
18.57
21.89
24.32
23.11
28.68
33.01
39.97
Return on Invested Capital (%)
20.89
23.25
19.71
26.68
23.78
25.08
20.96
20.61
21.83
21.3
25.25
52.79
45.51
78.79
73.27
76.19
817.08
Return on Capital (%)
20.63
23.21
19.61
26.66
23.75
25.06
20.86
20.56
21.8
21.29
25.34
53.42
46.24
80.88
75.64
79.32
1,576.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
53
- -
41
LT Borrowings
- -
- -
- -
LT Finance Leases
140
- -
168
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
- -
23
Market Capitalization
140,972
131,907
146,839

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
11,268
- -
7,803
Cash, Cash Equivalents & STI
3,400
- -
3,129
Accounts Receivable, Net
2,300
- -
1,614
Inventories
4,998
- -
2,717
Total Current Liabilities
7,365
- -
4,220
Payables & Accruals
- -
- -
- -
ST Debt
53
- -
41
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.52%
-17.25%
-12.94%
Free Cash Flow
15.82%
6.06%
-2.99%
Net Income, GAAP
5.09%
1.64%
-20.99%
Sales/Revenue/Turnover
-1.06%
-8.02%
-8.33%
Total Cash Common Dividend
43.91%
1.24%
14.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,108
4,635
5,240
5,149
19,890
2025
5,359
4,063
4,198
- -
18,234
2026
4,723
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
59.31
44.9
35.69
39.64
179.54
2025
51.89
30.18
26.79
- -
141.85
2026
44.55
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
167
2025
- -
- -
- -
- -
192.01
2026
- -
- -
- -
- -
- -
Similar Companies
PT Kalbe Farma Tbk (PTKFY)
Qingdao Baheal Medical Inc. (301015.SZ)
AbbVie Inc. (4AB.DU)
AstraZeneca PLC (AZN.L)
Roche Holding AG (0QQ6.L)
Orion Oyj (ORNBV.HE)
Business
Sanofi India Limited, a subsidiary of Sanofi S.A., manufactures and markets pharmaceutical products, vaccines and consumer healthcare offerings in India. The company provides a broad portfolio of prescription medicines across therapeutic areas including diabetes with brands such as Lantus, Toujeo, Apidra, Amaryl, Amaryl M, Cetapin and Soliqua; cardiology and thrombosis with Cardace, Cardace Protect, Cardace AM, Cardace H, Cardace Meto, Clexane, Plavix and Telsite; neurology and epilepsy with Depakote, Depakote XR, Frisium, Valparin, Vinlep and Solian; anti-infectives and vaccines such as Fluquadri, Hexaxim and Beyfortus; rare diseases and transplants with Aldurazyme, Cerezyme, Fabrazyme, Myozyme, Thymoglobuline and Rezurock; pain management and others including Combiflam, Allegra, Lasix, Myoril and Taxotere; as well as consumer healthcare products like Maalox and Enterogermina. Incorporated in 1956 and headquartered in Mumbai at Sanofi House, Powai, the company operates manufacturing facilities in India with products distributed domestically and exported to developed and developing markets, employing around 3,000 people. In recent developments, Sanofi India entered an exclusive distribution partnership with Dr. Reddy's Laboratories in 2024 for its vaccine brands in private markets; partnered with Cipla for its CNS portfolio; announced an exclusive distribution and promotion agreement with Emcure Pharmaceuticals in July 2025 for oral anti-diabetic products including Amaryl and Cetapin; launched Soliqua in April 2024 and received marketing authorizations for Rezurock in February 2025 and Beyfortus in July 2024; while Sanofi Healthcare India expanded its Hyderabad global capability centre with a €400 million investment planned through 2030 to support AI-driven operations and host up to 2,600 employees.